A Phase 2, Multi-center, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of ONO-2952 in Female Subjects With Diarrhea-Predominant Irritable Bowel Syndrome (IBS-D)

Trial Profile

A Phase 2, Multi-center, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of ONO-2952 in Female Subjects With Diarrhea-Predominant Irritable Bowel Syndrome (IBS-D)

Completed
Phase of Trial: Phase II

Latest Information Update: 07 Nov 2016

At a glance

  • Drugs ONO 2952 (Primary)
  • Indications Irritable bowel syndrome
  • Focus Proof of concept; Therapeutic Use
  • Acronyms RESTORE
  • Sponsors Ono Pharmaceutical
  • Most Recent Events

    • 07 Nov 2016 Primary endpoint Abdominal pain or stool symptoms in female subjects with IBS-D by using a numeric pain rating scale and the Bristol Stool Scale (BSS) has not been met, according to Results published in the Alimentary Pharmacology and Therapeutics.
    • 07 Nov 2016 Results assessing safety and efficacy published in the Alimentary Pharmacology and Therapeutics
    • 29 Aug 2014 Status changed from recruiting to completed as reported by ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top